Skip to main content

Health condition

MPNST in NF1

Malignant peripheral nerve sheath tumour (MPNST) is the most feared complication of neurofibromatosis type 1, arising in a plexiform neurofibroma; new persistent pain, rapid growth or hardening of a known lesion demands urgent imaging and sarcoma referral.

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against current NHS and UK specialist society guidance at the time of review.

  • 03

    Current for 2026

    Reviewed on 2026-09-27 with the next review scheduled for 2027-09-27.

Key facts

The essentials at a glance.

The symptoms to recognise, when to seek help, which specialist to see, and what treatment usually involves.

  • People with NF1 carry a significant lifetime risk of MPNST, highest in young adulthood

  • Warning signs: new unremitting pain, rapid enlargement, hardening or new weakness in a known neurofibroma

  • Whole-body MRI and FDG-PET help find and characterise suspicious lesions

  • Complete surgical excision at a sarcoma centre is the only reliably curative treatment

Understanding the condition

What it is and what happens next.

What causes it, how it is diagnosed, and the treatment routes available in the UK.

What it is and how it feels

Within NF1, large internal plexiform neurofibromas - present in perhaps half of patients, often invisibly - are the soil from which MPNST grows. The transformation announces itself as change: a lesion that always ached now hurts constantly and at night, enlarges over weeks, feels firmer, or begins to disturb nerve function. Because people with NF1 live with many lumps and chronic symptoms, both patients and clinicians need an explicit low threshold for investigating changed lesions rather than attributing everything to the underlying condition.

Diagnosis and treatment routes

Assessment moves quickly through MRI and PET to planned core biopsy at a sarcoma unit, since grade and margins govern everything. Wide, complete excision offers the main chance of cure; radiotherapy assists local control, while conventional chemotherapy adds modestly - keeping trials, including targeted approaches arising from NF1 biology, firmly relevant. For higher-risk patients, structured surveillance with whole-body MRI, and specialist NF1 clinic follow-up, aim to catch transformation at its earliest, most operable moment. If you are waiting for results or want a second opinion on a proposed plan, a private consultation with a specialist who treats this condition regularly can usually be arranged quickly, and most will review your existing scans, biopsy reports and MDT correspondence.

Seeing a specialist

Who to see, and how quickly you can be seen.

The specialist for this condition is usually a consultant sarcoma specialist. Your GP can refer you on the NHS, or you can arrange a private consultation directly.

A quiet reminder

This guide is for information, not medical advice.

Your GP knows your history and can tell you which parts apply to you. If in doubt, see them - and seek urgent care for any of the emergency symptoms described above.

Frequently asked

Common questions about MPNST in NF1.

Quick, plain-English answers to what people ask us most.

  • What is MPNST in NF1?

    MPNST stands for malignant peripheral nerve sheath tumour, a rare but serious cancer that can develop from benign nerve tumours called neurofibromas in people with neurofibromatosis type 1, a genetic condition affecting nerve tissue growth.

  • What causes MPNST to develop in NF1?

    MPNST arises when a pre-existing benign neurofibroma undergoes malignant transformation, thought to result from accumulating additional genetic changes on top of the underlying NF1 gene mutation, though the exact trigger for transformation in a given tumour isn't always clear.

  • What symptoms suggest MPNST rather than a benign neurofibroma in someone with NF1?

    Warning signs include a plexiform neurofibroma that suddenly grows rapidly, becomes persistently painful, changes texture, or causes new neurological symptoms such as weakness or numbness, which differ from the typically stable, painless nature of benign neurofibromas.

  • Is MPNST dangerous?

    Yes, MPNST is an aggressive cancer with a higher risk of spreading compared with many other soft tissue sarcomas, making early detection and prompt specialist treatment particularly important for people with NF1.

  • Is NF1-associated MPNST hereditary?

    The underlying NF1 condition is inherited in an autosomal dominant pattern, but MPNST itself is not separately inherited; rather, it's a complication that develops in a minority of people who already have NF1.

  • How is MPNST in NF1 monitored for and treated?

    People with NF1 are advised to report any rapidly growing or newly painful nerve tumour promptly, with MRI and sometimes PET scanning used to assess suspicious lesions, and treatment for confirmed MPNST typically involving surgery, often combined with radiotherapy.

  • When should someone with NF1 seek urgent specialist assessment for a changing neurofibroma?

    Seek prompt specialist assessment for any neurofibroma that grows quickly, becomes newly painful, or causes new neurological symptoms, as timely evaluation is important; a specialist NF1 clinic or private neurologist or oncologist can typically arrange urgent imaging and assessment within about one to two weeks.